David Younger is a postdoc in Bioengineering who is commercializing the work from his Ph.D. at A-Alpha Bio. Read more to learn about how the teamwork and scientific skills he built from his undergrad and Ph.D. were a perfect fit for his current challenge to build a startup.
UW Bioengineering faculty member Jay Rubinstein was inducted to the AIMBE College of Fellows Class of 2019.
Becky Darrow is a senior in the Department of Bioengineering at UW, and she will work as a consultant at Accenture after graduation. Read more to learn about her love of dance and lessons she learned throughout college.
Adam Little is an undergraduate senior in bioengineering. Read more to learn about how Adam discovered that the most important skills he took from college were not technical skills, but instead interpersonal and interdisciplinary ways of thinking about human health.
Two ideas put forth by UW's Center for Dialysis Innovation (CDI) - a next-generation wearable dialyzer and a new vascular access graft - advanced to the finals in a national competition aimed at speeding innovations in prevention, diagnosis and treatment of kidney diseases.
Bioprinted tissues with entangled vascular networks for air and blood are a major step toward 3D printing of replacement organs. Bioengineers from University of Washington and Rice University teamed to create the 3D bioprinted vascular networks and tested them in mice.
Jayleen Leon is a junior in the Department of Bioengineering at UW, and wants to continue her education in graduate school. Read more to learn about her journey to BioE.
Levi Devis is a senior in the Department of Bioengineering at UW, and wants to continue his education in graduate school. Read more to learn about his transition from community college to UW.
Bonnibelle Leeds is a senior in the Department of Bioengineering at UW, and wants to continue her education in graduate school. Read more to learn about her transition from community college to UW.
Researchers led by UW Department of Bioengineering Professor Valerie Daggett have developed synthetic peptides that can target and inhibit the small, toxic protein aggregates that are thought to trigger Alzheimer’s disease. The team reports their achievement in a paper published the week of April 15 in the Proceedings of the National Academy of Sciences.
